Reuters: Regulatory News: Bayer says lung drug shows promise in prolonged trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Bayer says lung drug shows promise in prolonged trial May 20th 2013, 19:00 FRANKFURT | Mon May 20, 2013 3:00pm EDT FRANKFURT May 20 (Reuters) - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a prolonged trial. In the extension of a late-stage trial, the drug was shown to help people suffering from pulmonary arterial hypertension (PAH), a progressively worsening condition that can overburden the heart, to better tolerate physical exercise. It said that side effects, including headache, dizziness, indigestion and low blood pressure, were tolerable. Bayer has said it expects peak annual sales of more than 500 million euros ($646 million) from the product and analysts polled by Thomson Reuters Pharma on average see 2017 sales from riociguat of $679 million, posing a potential challenge to existing treatments from Actelion and Gilead. Preliminary results of the study were published in October, encouraging Bayer to earlier this year submit riociguat for regulatory approval in the United States and Europe.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions